Inactive Instrument

BioPlus Acquisition Corp.

BIOS

KYG112171171

BioPlus Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 10, 2022 at 04:32 pm EDT

BioPlus Acquisition Corp. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net income was USD 0.024921 million compared to net loss of USD 0.00114 million a year ago.
For the six months, net loss was USD 0.236901 million.

Latest news about BioPlus Acquisition Corp.

BioPlus Acquisition Corp.(NasdaqGM:BIOS) dropped from NASDAQ Composite Index	23-10-10	CI
BioPlus Acquisition, Avertix Medical Terminate Business Combination Deal	23-10-04	MT
Avertix Medical, Inc. terminated the acquisition of BioPlus Acquisition Corp. from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others in a reverse merger transaction.	23-10-03	CI
BioPlus Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
BioPlus Acquisition Corp. announced that it has received $1.5 million in funding	23-06-01	CI
BioPlus Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Avertix Medical, Inc. entered into a definitive merger agreement to acquire BioPlus Acquisition Corp. from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others for approximately $170 million in a reverse merger transaction.	23-05-02	CI
BioPlus Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
BioPlus Acquisition Corp. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
BioPlus Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
BioPlus Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
Certain Class B Ordinary Shares of BioPlus Acquisition Corp. are subject to a Lock-Up Agreement Ending on 1-JUN-2022.	22-05-31	CI
BioPlus Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
BioPlus Acquisition Corp. Reports Earnings Results for the Eleven Months Ended December 31, 2021	22-03-11	CI
BioPlus Acquisition Corp.(NasdaqGM:BIOS) added to NASDAQ Composite Index	22-01-31	CI
BioPlus Acquisition Corp. has completed an IPO in the amount of $200 million.	21-12-02	CI
BioPlus Acquisition Corp. has filed an IPO in the amount of $220 million.	21-07-19	CI

Chart BioPlus Acquisition Corp.

Duration

Period

More charts

Company Profile

BioPlus Acquisition Corp. is a blank check company. The Company is formed for the purpose effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search on companies in the life sciences industry. The Company has not commenced any operations nor generated any revenue.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+119.94%	5.26B
SCREAMING EAGLE ACQUISITION CORP.	+1.60%	1.01B
CHURCHILL CAPITAL CORP VII	+2.29%	983M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+27.64%	834M
ARES ACQUISITION CORPORATION II	+1.68%	663M
E7 GROUP	+2.15%	617M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ALTC ACQUISITION CORP.	+23.11%	560M

Shell Companies